Rivaroxaban versus warfarin in nonvalvular atrial fibrillation [1]

New England Journal of Medicine

Volumn 365, Issue 24, 2011, Pages 2333-2335

  Niessner, Alexander ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; DABIGATRAN; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE;

DRUG EFFICACY; DRUG SAFETY; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; INTENTION TO TREAT ANALYSIS; LETTER; PRIORITY JOURNAL; STROKE; ANTICOAGULANT THERAPY; COST EFFECTIVENESS ANALYSIS; INTERNATIONAL NORMALIZED RATIO; PHARMACOLOGICAL PARAMETERS; TIME IN THE THERAPEUTIC RANGE; FEMALE; MALE; NOTE;

ANTICOAGULANTS; ATRIAL FIBRILLATION; FEMALE; HUMANS; MALE; MORPHOLINES; THIOPHENES; WARFARIN;

EID: 84856173585     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1112233     Document Type: Letter

References (2)

1. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
2. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010;152:726-32.